Revenue
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals, Inc. (AMLX)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $87.4M | $380.8M | $22.2M | $285,000 |
| Research & development | $90.4M | $104.1M | $2.7M | $22.9M | $44.0M |
| Operating income | −$153.3M | −$314.7M | $38.8M | −$201.3M | −$82.7M |
| Net income | −$144.7M | −$301.7M | $49.3M | −$198.4M | −$87.9M |
| Basic EPSper diluted share | -$1.53 | -$4.43 | $0.73 | -$3.39 | -$13.35 |
| Diluted EPSper diluted share | -$1.53 | -$4.43 | $0.70 | -$3.39 | -$13.35 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 21, 2026Form 4 | Firestone KarenDirector | BuyCommon Stock | 3.8K | $13.51 | $51.3K | 66.9K |
| Mar 2, 2026Form 4 | Klee Justin B.Co-Chief Executive Officer | SellCommon Stock | 29.3K | $14.47 | $423.7K | 3.33M |
| Mar 2, 2026Form 4 | Cohen Joshua BCo-Chief Executive Officer | SellCommon Stock | 29.3K | $14.48 | $424.0K | 3.33M |
| Mar 2, 2026Form 4 | Bedrosian Camille LChief Medical Officer | SellCommon Stock | 6.5K | $14.58 | $94.2K | 169.3K |
| Mar 2, 2026Form 4 | FRATES JAMES MChief Financial Officer | SellCommon Stock | 7.9K | $14.52 | $114.8K | 165.6K |